Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-β-cyclodextrin complex

AAPS PharmSciTech

Volumn 15, Issue 1, 2014, Pages 121-130

  Ren, Lili ^a   Zhou, Yu ^a   Wei, Ping ^a   Li, Min ^a   Chen, Guoguang ^a  

^a NANJING TECH UNIVERSITY   (China)

Author keywords

aprepitant; bioavailability; dissolution rate; inclusion complex; sulfobutyl ether cyclodextrin

Indexed keywords

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DOGS; MORPHOLINES; NANOPARTICLES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TANDEM MASS SPECTROMETRY; X-RAY DIFFRACTION;

EID: 84893761743     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-0044-0     Document Type: Article

References (22)

1. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, et al. Comparison of L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37:835-42.
2. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. N Engl J Med. 1999;340:190-5.
3. De Wit R, Hesketh PJ, Warr D, Petty K, Carides AD, Evans JK, et al. The oral NK1 antagonist aprepitant for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy: a review. Am J Cancer. 2005;4:35-48.
4. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu GH, et al. Lack of efficacy of the substance P(Neurokinin 1 Receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59:216-23.
5. Olver I, Shelukar S, Thompson KC. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine. 2007;2:13-8.
6. Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressman JB. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm. 2010;76:95-104.
7. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-8.
8. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3-19.
9. Urbanetz NA, Lippold BC. Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterisation Original Research Article. Eur J Pharm Biopharm. 2005;59:107-18.
10. Singhal S, Lohar VK, Arora V. Hot melt extrusion technique. WebmedCentral Pharm Sci. 2011;2(1).
11. Zingone G, Rubessa F. Preformulation study of the inclusion complex warfarin-β-cyclodextrin. Int J Pharm. 2005;291:3-10.
12. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-25.
13. Robert O, Williams III, Mahaguna V, Sriwongjanya M. Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin. Eur J Pharm Biopharm. 1998;46:355-60.
14. Waleczek KJ, Cabral Marques HM, Hempel B, Schmidt PC. Phase solubility studies of pure (-)-α-bisabolol andcamomile essential oil with β-cyclodextrin. Eur J Pharm Biopharm. 2003;55:247-51.
15. Liu LX, Zhu SY. Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β- cyclodextrin. J Pharm Biomed Anal. 2006;40:122-7.
16. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117-212.
17. Ridhurkar DN, Ansari KA, Kumar D, Kaul NS, Krishnamurthy T, Dhawan S, et al. Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Drug Dev Ind Pharm. 2013;39(11):1783-92.
18. Loftsson T, Hreindótter D, Másson M. The complexation efficiency. J Incl Phenom Macrocycl Chem. 2007;57:545-52.
19. Wu YH, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285:135-46.
20. Fernandes CM, Teresa Vieira M, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci. 2002;15:79-88.
21. Liu LX, Zhu SY. A study on the supramolecular structure of inclusion complex of β-cyclodextrin with prazosin hydrochloride. Carbohydr Polym. 2007;68:472-6.
22. Loukas YL, Vraka V, Gregoriadis G. Drugs in cyclodextrins, in liposomes: a novel approach to the chemical stability of drugs sensitive to hydrolysis. Int J Pharm. 1998;162:137-42.